Iterum Therapeutics PLC reports results for the quarter ended in December - Earnings Summary

Iterum Therapeutics

28/03/2024 13:31

* Iterum Therapeutics PLC  ITRM.OQ  reported a quarterly
adjusted
loss of 94 cents​​ per share for the quarter ended in December. 
The mean expectation of two analysts for the quarter was for a
loss of 93 cents per share. Wall Street expected results to
range from $-1.02 to -85 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Iterum Therapeutics PLC's reported EPS for the quarter was
a
loss of 94 cents​.
    * The company reported a quarterly loss of $12.36 million.
    * Iterum Therapeutics PLC shares had fallen by 19.3% this
quarter.

FORECAST CHANGES
    * The mean earnings estimate of analysts had fallen by
about 3.9%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"

Wall Street's median 12-month price target for Iterum
Therapeutics PLC is $6.50 
This summary was machine generated from LSEG data March 28 at
01:31 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2023      -0.93          -0.94          Missed
 Sep. 30 2023      -0.91          -0.30          Beat
                                  -0.95          
                                  -0.78